Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
I last covered Recursion Pharmaceuticals (RXRX) for Seeking Alpha back in February, when I gave the company's stock a "HOLD" rating and suggested that the company was "not yet derisking drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results